CAMBRIDGE, Mass, January 26, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that management will present at the Guggenheim Healthcare Talks 2023 Oncology Day, being held February 8-9, 2023, in New York, NY. Daniel Getts, Ph.D., CEO of Myeloid, will present a company overview on Wednesday, February 8, 2023, at […]
CAMBRIDGE, Mass, January 5, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that Daniel Getts, Ph.D., CEO of Myeloid, will present at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023, in San Francisco, CA. The company is scheduled to present on Thursday, January 12, 2023, at […]
CAMBRIDGE, Mass, Nov. 10, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that the Company will participate at the Jefferies London Healthcare Conference taking place from November 15-17, 2022 in London. Company management will meet one-on-one with investors during the conference. About Myeloid Therapeutics Myeloid Therapeutics is a clinical […]
Myeloid Therapeutics Presents Update On Myeloid Cell Programming Technologies, Including Non-Human Primate Proof-Of-Concept Data Delivering in vivo mRNA TROP-2 Targeting CAR (MT-302) at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting -New preclinical data on lead in vivo programming program, MT-302, demonstrates strong expression and favorable safety in myeloid cells following a single administration […]
Myeloid Therapeutics Announces FDA Fast Track Designation for MT-101 for the Treatment of CD5+ Relapsed/Refractory PTCL CAMBRIDGE, Mass, October 27, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage mRNA-immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MT-101 in patients with refractory or relapsed CD5+ peripheral […]
CAMBRIDGE, Mass, September 8, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company harnessing the power of myeloid and innate biology to engineer novel therapies that elicit a broad immune response for cancer and autoimmune diseases, today announced that the Company will participate in the following investor conferences: Morgan Stanley 20th Annual Global […]
Myeloid Therapeutics Strengthens Senior Team to Support the Expansion of its Manufacturing Capabilities CAMBRIDGE, Mass, August 23, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company harnessing the power of myeloid and innate biology to engineer novel therapies that elicit a broad immune response for cancer and autoimmune diseases, today announced that it […]
Myeloid Therapeutics Strengthens its Board of Directors with Appointments of Stanley Frankel, M.D., FACP and Brett Kaplan, M.D. CAMBRIDGE, Mass, June 30, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company harnessing the power of myeloid and innate biology to engineer novel therapies that elicit a broad immune response for cancer and autoimmune […]
CAMBRIDGE, Mass, May 24, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases, today announced that it will participate in the following investor conferences during June 2022: Wells Fargo Private Biotech Symposium, taking place virtually on June 1, 2022 Healthcare Conference, taking place in New […]
Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle System..
Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans – Myeloid’s monocyte-specific CAR technology combined with Acuitas’ industry-leading LNP portfolio will accelerate in vivo cell programming for cancer patients – – This strategic step complements Myeloid’s existing pipeline and illustrates its […]